NDA 213400 · Epizyme INC
Tazverik
Tazemetostat Hydrobromide · Oral
Accelerated approvalPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jun 18, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jun 18, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 0 recruiting
FAERS reports
1,622
721 serious, 216 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 18, 2020 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · priority review Accelerated approvalOrphanLabelMedication GuideLetter
1 products under this application
- TAZVERIK · TAZEMETOSTAT HYDROBROMIDE 200MG · TABLET, ORAL · Prescription · TE TBD
Clinical trials
Interventional ClinicalTrials.gov studies with "Tazemetostat Hydrobromide" as an intervention, any sponsor and status, largest first.
National Cancer Institute (NCI)NIH
NCT05353439 · 22 participants · Start Jul 27, 2022 · Primary completion Feb 11, 2026
Drug: Pembrolizumab; Tazemetostat Hydrobromide and 1 more · For: Extensive Stage Lung Small Cell Carcinoma; Limited Stage Lung Small Cell Carcinoma; Platinum-Resistant Lung Small Cell Carcinoma and 3 more
Sites: Los Angeles, California; Newport Beach, California; Sacramento, California · 15 sites in all
- Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual TreatmentActive, not recruiting
National Cancer Institute (NCI)NIH
NCT04557956 · 16 participants · Start Aug 19, 2021 · Primary completion Oct 15, 2025
Drug: Dabrafenib Mesylate; Tazemetostat Hydrobromide and 1 more · For: Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma
Sites: Aventura, Florida; Coral Gables, Florida; Deerfield Beach, Florida · 17 sites in all
Eric Jacobsen, MDAcademic, hospital or other
NCT06692452 · 0 participants · Start Dec 24, 2024 · Primary completion Oct 1, 2027
Drug: Tazemetostat; Doxorubicin and 7 more · For: Lymphoma; Peripheral T Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma and 2 more
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use335
- fatigue326
- disease progression305
- nausea235
- product dose omission issue212
- death132
- diarrhoea123
- decreased appetite97
- vomiting95
- asthenia83
- constipation80
- headache74
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 3 |
| 2018 | 11 |
| 2019 | 6 |
| 2020 | 81 |
| 2021 | 256 |
| 2022 | 395 |
| 2023 | 316 |
| 2024 | 205 |
| 2025 | 242 |
| 2026 | 107 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Tazverik (Tazemetostat Hydrobromide)
2024 spending
$25.1M
Beneficiaries
228
1,417 claims
Per beneficiary
$110,237
$81.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $2,816,560 |
| 2021 | $8,150,727 |
| 2022 | $14,801,232 |
| 2023 | $18,985,929 |
| 2024 | $25,134,062 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
Proudman D, Nellesen D, Gupta D, et al. · Adv Ther 2022 · Systematic Review, Research Support, Non-U.S. Gov't
Sponsor: Epizyme INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.